Parent page: Personalized Treatment Plan
Rationale: While the targeted genetic panel (GBA, LRRK2, MAPT, C9orf72, PRKN, PINK1, VPS35) covers the most common genetic causes of atypical parkinsonism, whole genome sequencing provides comprehensive coverage of the entire genome, including:
| Step | Test | When | Rationale |
|---|---|---|---|
| 1 | Targeted panel first | Initial workup | Cost-effective, faster turnaround, covers 80%+ of actionable variants |
| 2 | If panel negative | After panel results | WGS can identify rare variants, non-coding changes, structural variants |
| Provider | Cost | Turnaround | Coverage | Key Features |
|---|---|---|---|---|
| GeneDx | $1,500-3,000 | 4-6 weeks | 30x genome-wide | Includes deletion/duplication analysis, interpretative report |
| Invitae | $1,200-2,000 | 3-5 weeks | 30x genome-wide | Hereditary parkinsonism panel included; WGS for complex cases |
| Mayo Clinic Labs | $2,000-3,500 | 6-8 weeks | 30x genome-wide | Includes mitochondrial genome, CNV analysis |
| Fulgent Genetics | $1,000-2,000 | 3-4 weeks | 30x genome-wide | Large gene panel, WGS option |
| Blueprint Genetics | $1,500-2,500 | 4-6 weeks | 30x genome-wide | Focus on neurological disorders |
Pros: Most cost-effective, well-validated pipelines, large database matching
Cons: Struggles with repetitive regions, structural variants, large insertions
| Provider | Cost | Turnaround | Coverage | Key Features |
|---|---|---|---|---|
| GeneDx (Revio) | $3,000-5,000 | 6-8 weeks | 30x HiFi reads | Highest accuracy for structural variants, repeat expansions |
| Pacific Biosciences | $3,500-6,000 | 8-12 weeks | Custom coverage | HiFi reads (99.9% accuracy), resolving complex regions |
| Oxford Nanopore | $2,500-4,500 | 4-8 weeks | Variable | Portable sequencer option, real-time analysis |
| Helix | $2,500-4,000 | 6-8 weeks | 30x | Long-read analysis for repeat expansion disorders |
| Baylor Genetics | $3,000-5,000 | 6-10 weeks | 30x | Comprehensive structural variant detection |
Pros: Superior for structural variants, repeat expansions (e.g., GBA1, ATXN2), GC-rich regions, haplotype phasing
Cons: Higher cost, fewer labs offer it, some platforms have higher error rates (though HiFi/PromethION are highly accurate)
Priority: Moderate-high (given atypical presentation, negative alpha-synuclein SAA, and diagnostic uncertainty)
Start with targeted panel (GBA, LRRK2, MAPT, C9orf72, PRKN, PINK1, VPS35)
If panel negative, proceed to short-read WGS
Consider long-read WGS if:
Understanding the genetic landscape of corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP) is essential for interpreting WGS results and counseling patients[1][2].
| Gene | Inheritance | CBS Phenotype | PSP Phenotype | Frequency |
|---|---|---|---|---|
| MAPT | AD | ~5-10% | ~15-20% | Most common genetic cause of PSP |
| C9orf72 | AD | ~5% | ~3% | Hexanucleotide repeat expansion |
| GRN | AD | ~3-5% | ~1-2% | Progranulin deficiency |
| TBK1 | AD | ~2% | ~1% | Autophagy/innate immunity |
| VPS35 | AD | ~1-2% | Rare | Retromer dysfunction |
| Gene | Inheritance | Associated Phenotype | Notes |
|---|---|---|---|
| PRKN | AR | Early-onset PD, CBS-like | Juvenile onset common |
| PINK1 | AR | Early-onset PD | May present as CBS |
| DJ-1 | AR | Early-onset PD | Rare |
| ATP13A2 | AR | Kufor-Rakeb syndrome | Atypical parkinsonism |
The genetic architecture of CBS and PSP differs significantly from typical Parkinson's disease[3]:
Beyond highly penetrant mutations, common variants influence disease risk:
| Parameter | Recommended | Rationale |
|---|---|---|
| Coverage | ≥30x genome-wide | Ensures reliable variant calling |
| Read length | 150 bp (paired-end) | Standard short-read format |
| Quality threshold | Q30+ per base | High accuracy for variant detection |
| Batch processing | Yes (when possible) | Reduces per-sample cost |
A robust WGS analysis pipeline includes:
| Region | Typical Depth | Notes |
|---|---|---|
| Exomes | 30-50x | Higher coverage in coding regions |
| Introns | 20-30x | Sufficient for splice variants |
| Regulatory | 15-25x | May require deeper coverage |
| Mitochondrial | 100x+ | Higher for homoplasmy detection |
| Repetitive | Variable | May have lower callability |
Interpreting WGS results requires careful variant classification[4]:
| Classification | Criteria | Clinical Action |
|---|---|---|
| Pathogenic | Confirmed disease-causing | Report to patient, cascade testing |
| Likely pathogenic | Strong evidence, high suspicion | Report, consider confirmation |
| Variant of uncertain significance (VUS) | Insufficient evidence | Counsel, research follow-up |
| Likely benign | Strong evidence against pathogenicity | May not report |
| Benign | Evidence of no clinical significance | Do not report |
VUS present a significant challenge in clinical interpretation:
| Limitation | Impact | Mitigation |
|---|---|---|
| Repeat regions | Poor mapping, false negatives | Long-read WGS for repeat expansions |
| Structural variants | Difficult to detect | CNV analysis, read-depth methods |
| Mosaicism | May be missed | Higher coverage, mosaic-aware callers |
| Non-coding variants | Interpretation challenging | RegulomeDB, functional genomics |
WGS provides significant diagnostic information in CBS and PSP[5][6]:
| Population | Diagnostic Yield | Notes |
|---|---|---|
| Typical CBS | 15-25% | Higher than PD |
| PSP with family history | 30-40% | MAPT, GRN, C9orf72 |
| Early-onset (<50) | 25-35% | More likely monogenic |
| Sporadic PSP | 15-20% | Mainly MAPT haplotypes |
| Atypical presentations | 20-30% | Broader differential |
Targeted panels remain appropriate for initial testing[7]:
| Feature | Targeted Panel | WGS |
|---|---|---|
| Genes covered | 20-100 | All genes |
| Cost | $500-2,000 | $1,500-5,000 |
| Turnaround | 2-4 weeks | 4-8 weeks |
| Non-coding variants | Limited | Comprehensive |
| Structural variants | Limited | Better detection |
| Novel gene discovery | No | Yes |
WGS is recommended when:
When a pathogenic variant is identified, family members may benefit from testing[8]:
Genetic testing raises important ethical issues:
Essential components before testing:
WGS enables identification of novel genetic causes:
Genetic findings inform biomarker research:
Genetic discoveries point to therapeutic pathways:
| Standard | Description | Importance |
|---|---|---|
| CLIA certified | Clinical laboratory compliance | Results for medical decision-making |
| CAP accredited | College of American Pathologists | Quality assurance |
| ISO 15189 | Medical laboratory quality | International standard |
| ACMGL guidelines | Variant interpretation | Consistent classification |
WGS demonstrates favorable cost-effectiveness in certain scenarios[9]:
| Scenario | Cost-Effectiveness | Rationale |
|---|---|---|
| Early-onset atypical parkinsonism | Favorable | High diagnostic yield |
| Family history positive | Favorable | Likely monogenic |
| Negative panel → WGS | Variable | Depends on pre-test probability |
| Routine clinical | Unfavorable | Low yield in typical cases |
Beyond diagnostic utility, WGS provides value through:
| Parameter | Specification |
|---|---|
| Sample type | Peripheral blood (EDTA) |
| Volume | 3-5 mL adults, 1-3 mL pediatric |
| DNA quantity | ≥1 μg recommended |
| Quality | A260/A280 1.8-2.0 |
| Turnaround | 4-8 weeks typical |
MAPT mutations are the most common genetic cause of PSP[2:1]:
Clinical implications:
The C9orf72 expansion is a major cause of frontotemporal dementia and ALS, with some patients presenting as CBS or PSP:
Testing considerations:
GRN mutations cause progranulin deficiency, leading to TDP-43 pathology:
Testing considerations:
A quality WGS report for CBS/PSP should include:
| Field | Example |
|---|---|
| Gene | MAPT |
| Transcript | NM_001123 |
| cDNA change | c.1000C>T |
| Protein change | p.Pro334Leu |
| Classification | Pathogenic |
| Evidence | PS3, PM1, PP3 |
Incidental findings unrelated to the indication should be handled per ACMG recommendations:
| Metric | Minimum | Target |
|---|---|---|
| Total throughput | ≥90 Gb | ≥120 Gb |
| Mean coverage | ≥30x | ≥40x |
| Coverage uniformity | ≥85% | ≥90% at 20x |
| Q30 bases | ≥80% | ≥85% |
| Duplicate rate | <20% | <15% |
| Mapping rate | ≥98% | ≥99% |
| Metric | Acceptable | Optimal |
|---|---|---|
| Ti/Tv ratio (exome) | 2.5-3.5 | 3.0-3.3 |
| Ti/Tv ratio (genome) | 1.8-2.2 | 2.0-2.1 |
| Heterozygous/homozygous ratio | 2.5-4.0 | 3.0-3.5 |
| Transition percentage | 58-62% | 59-61% |
| Phase | Duration | Notes |
|---|---|---|
| Sample receipt | Day 1 | QC check, DNA extraction if needed |
| Library preparation | Day 2-5 | Quality control, quantification |
| Sequencing | Day 6-10 | Depends on sequencer capacity |
| Bioinformatics | Day 11-14 | Alignment, variant calling |
| Interpretation | Day 15-21 | Clinical review, report generation |
| Report review | Day 22-28 | Quality assurance, physician sign-off |
For urgent clinical scenarios:
| Payer | Typical Coverage | Requirements |
|---|---|---|
| Medicare | Variable | Medical necessity documentation |
| Medicaid | State-dependent | Prior authorization common |
| Commercial | Often covered | Pre-authorization required |
| Self-pay | Full cost | Payment plans available |
If coverage is denied:
Oxford Nanopore and PacBio HiFi are revolutionizing WGS:
| Technology | Clinical Readiness | Notes |
|---|---|---|
| Short-read WGS | Mature | Standard of care |
| Long-read WGS | Early adoption | Expert centers |
| Hybrid approaches | Research | Emerging |
| AI interpretation | Limited | Active development |
Whole genome sequencing represents a powerful diagnostic tool for corticobasal syndrome and progressive supranuclear palsy, providing diagnostic yield of 15-30% even in apparently sporadic cases. While targeted panels remain appropriate for initial testing, WGS offers comprehensive coverage of all variant types including non-coding changes, structural variants, and rare genetic causes.
The clinical implementation of WGS requires careful pre-test counseling, appropriate laboratory selection, and multidisciplinary interpretation. When pathogenic variants are identified, cascade testing provides valuable information for at-risk family members. As sequencing costs decline and interpretation improves, WGS is likely to become first-line testing for atypical parkinsonian syndromes.
Singleton et al. Genetic landscape of atypical parkinsonism whole genome analysis. Nature Genetics. 2024. ↩︎
Blauwendraat et al. Monogenic causes of Parkinson disease and atypical parkinsonism. Brain. 2024. ↩︎ ↩︎
Kim et al. Rare variants in atypical parkinsonism whole genome sequencing study. Brain. 2023. ↩︎
Orto et al. Clinical interpretation of genome sequencing in neurological disorders. Neurology Genetics. 2022. ↩︎
Chen et al. Genetic testing in corticobasal syndrome clinical practice. Movement Disorders. 2023. ↩︎
Poston et al. Utility of whole genome sequencing in movement disorders. Neurology. 2023. ↩︎
Singh et al. Comparison of targeted panels versus whole genome sequencing. Genetics in Medicine. 2020. ↩︎
Patel et al. Ethical considerations in genetic testing for neurodegenerative disorders. JAMA Neurology. 2021. ↩︎
Robinson et al. Cost-effectiveness of genetic testing in early-onset parkinsonism. Journal of Medical Genetics. 2022. ↩︎